{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:42:31Z","timestamp":1792269751517,"version":"4.4.0"},"reference-count":141,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Thyroid eye disease (TED) is a rare disease that can lead to decreased quality of life, permanent disfigurement, and vision loss. Clinically, TED presents with exophthalmos, periorbital edema, extraocular muscle dysfunction, and eyelid retraction, and can lead to vision-threatening complications such as exposure to keratopathy and dysthyroid optic neuropathy (DON). Over the last several years, significant advancements have been made in the understanding of its pathophysiology as well as optimal management. Ethnic variations in the prevalence, clinical presentation, and risk of vision-threatening complications of TED are summarized, and risk factors associated with TED are discussed. Additionally, significant advances have been made in the management of TED. The management of TED traditionally included anti-inflammatory medications, orbital radiation therapy, orbital surgical decompression, and biologic therapies. Most recently, targeted therapies such as teprotumumab, an insulin-like growth factor-1 receptor antagonist, have been studied in the context of TED, with promising initial data. In this review, updates in the understanding and management of TED are presented with a focus on the international variations in presentation and management.<\/jats:p>","DOI":"10.4103\/ijo.ijo_3217_21","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T06:28:32Z","timestamp":1657607312000},"page":"2335-2345","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":37,"title":["Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management"],"prefix":"10.4103","volume":"70","author":[{"given":"Caroline Y","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bristol Eye Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T","family":"Wester","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin M","family":"Shriver","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Iowa, Iowa City, IA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/01676830903104561","article-title":"Thyroid eye disease:A historical perspective","volume":"28","author":"B\u00fcrgi","year":"2009","journal-title":"Orbit"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/EJE-11-0548","article-title":"Incidence of hyperthyroidism in Sweden","volume":"165","author":"Abraham-Nordling","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B3-20240828","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves'disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/cen.14296","article-title":"Prevalence of thyroid eye disease in Graves'disease:A meta-analysis and systematic review","volume":"93","author":"Chin","year":"2020","journal-title":"Clin Endocrinol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves'orbitopathy","volume":"11","author":"Bartalena","year":"2020","journal-title":"Front Endocrinol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves'ophthalmopathy:The GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","article-title":"Quality of life in patients with chronic thyroid eye disease in the United States","volume":"10","author":"Cockerham","year":"2021","journal-title":"Ophthalmol Ther"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1089\/thy.2017.0365","article-title":"Death by suicide in Graves'disease and Graves'orbitopathy:A nationwide Danish register study","volume":"27","author":"Ferl\u00f8v-Schwensen","year":"2017","journal-title":"Thyroid"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1089\/thy.2008.0044","article-title":"Prevalence, risk factors, and clinical features of thyroid-associated ophthalmopathy in multiethnic Malaysian patients with Graves'disease","volume":"18","author":"Lim","year":"2008","journal-title":"Thyroid"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2265.1992.tb01445.x","article-title":"Graves'ophthalmopathy in relation to cigarette smoking and ethnic origin","volume":"36","author":"Tellez","year":"1992","journal-title":"Clin Endocrinol"},{"key":"B12-20240828","first-page":"99","article-title":"Prevalence of Graves'ophthalmopathy in patients with Graves'disease presenting to a referral centre in north India","volume":"139","author":"Reddy","year":"2014","journal-title":"Indian J Med Res"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"5","DOI":"10.4137\/OED.S32169","article-title":"Severe ophthalmological complications of thyroid disease are rare in Ibadan, Southwestern Nigeria:Results of a pilot study","volume":"8","author":"Ogun","year":"2016","journal-title":"Ophthalmol Eye Dis"},{"key":"B14-20240828","first-page":"1","article-title":"Graves'thyroid ophthalmopathy in Ethiopian patients","volume":"39","author":"Teshome","year":"2001","journal-title":"Ethiopian Med J"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1155\/2017\/7843972","article-title":"Thyroid disorders in Central Ghana:The influence of 20 years of iodization","volume":"2017","author":"Sarfo-Kantanka","year":"2017","journal-title":"J Thyroid Res"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.4103\/ijo.IJO_104_20","article-title":"Clinical profile of thyroid eye disease and factors predictive of disease severity","volume":"68","author":"Muralidhar","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B17-20240828","first-page":"56","article-title":"A clinico-investigative profile in Graves'ophthalmopathy","volume":"40","author":"Khurana","year":"1992","journal-title":"Indian J Ophthalmol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"e026850","DOI":"10.1136\/bmjopen-2018-026850","article-title":"Missing female patients:An observational analysis of sex ratio among outpatients in a referral tertiary care public hospital in India","volume":"9","author":"Kapoor","year":"2019","journal-title":"BMJ Open"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4103\/ijo.IJO_1918_19","article-title":"Thyroid eye disease survey:An anonymous web-based survey in the Indian subcontinent","volume":"68","author":"Pradhan","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors:A tale of two antigens implicated in Graves'disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J. Immunol"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1210\/jc.2016-1315","article-title":"TSH\/IGF-1 receptor cross talk in Graves'ophthalmopathy pathogenesis","volume":"101","author":"Krieger","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/cells10020383","article-title":"Lessons learned from targeting IGF-I receptor in thyroid-associated ophthalmopathy","volume":"10","author":"Janssen","year":"2021","journal-title":"Cells"},{"key":"B23-20240828","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","article-title":"Expression of thyrotropin-receptor mRNA in healthy and Graves'disease retro-orbital tissue","volume":"342","author":"Feliciello","year":"1993","journal-title":"Lancet"},{"key":"B24-20240828","doi-asserted-by":"crossref","first-page":"e34173","DOI":"10.1371\/journal.pone.0034173","article-title":"Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves'disease:Apparent role of ADAM17","volume":"7","author":"Hoa","year":"2012","journal-title":"PLoS One"},{"key":"B25-20240828","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","article-title":"Immunoglobulins from patients with Graves'disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor","volume":"89","author":"Smith","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B26-20240828","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","article-title":"Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves'disease is mediated through the insulin-like growth factor I receptor pathway","volume":"170","author":"Pritchard","year":"2003","journal-title":"J Immunol"},{"key":"B27-20240828","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","article-title":"Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy","volume":"16","author":"Weightman","year":"1993","journal-title":"Autoimmunity"},{"key":"B28-20240828","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1beta in orbital fibroblasts:Implications for the pathogenesis of thyroid-associated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"key":"B29-20240828","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2265.2003.01708.x","article-title":"TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves'ophthalmopathy patients","volume":"58","author":"IMMJ","year":"2003","journal-title":"Clin Endocrinol"},{"key":"B30-20240828","first-page":"911","article-title":"CD4+T cells and the Th1\/Th2 imbalance are implicated in the pathogenesis of Graves'ophthalmopathy","volume":"17","author":"Xia","year":"2006","journal-title":"Int J Mol Med"},{"key":"B31-20240828","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41433-018-0279-9","article-title":"The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye"},{"key":"B32-20240828","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.survophthal.2009.06.009","article-title":"Immunopathogenesis of thyroid eye disease:Emerging paradigms","volume":"55","author":"Naik","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"B33-20240828","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED):Evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2021","journal-title":"Eye"},{"key":"B34-20240828","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B35-20240828","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B36-20240828","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","article-title":"Rundle and his curve","volume":"129","author":"Bartley","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"B37-20240828","first-page":"177","article-title":"Development and course of exophthalmos and ophthalmoplegia in Graves'disease with special reference to the effect of thyroidectomy","volume":"5","author":"Rundle","year":"1945","journal-title":"Clin Sci"},{"key":"B38-20240828","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/IOP.0000000000000371","article-title":"Recurrent thyroid eye disease","volume":"31","author":"Patel","year":"2015","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B39-20240828","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA Classification for Graves orbitopathy","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B40-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves'ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin. Endocrinol"},{"key":"B41-20240828","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves'orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves'orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"B42-20240828","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.eye.6702381","article-title":"Postural visual obscurations in patients with inactive thyroid eye disease;a variant of ''hydraulic''disease","volume":"20","author":"Rose","year":"2006","journal-title":"Eye"},{"key":"B43-20240828","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.4103\/ijo.IJO_2284_19","article-title":"Visual morbidity in thyroid eye disease in Asian Indian patients","volume":"68","author":"Gupta","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B44-20240828","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0002-9394(14)72787-4","article-title":"Diagnostic criteria for Graves'ophthalmopathy","volume":"119","author":"Bartley","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"B45-20240828","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0002-9394(77)90140-4","article-title":"Modification of the classification of the eye changes of Graves'disease","volume":"83","author":"Werner","year":"1977","journal-title":"Am J Ophthalmol"},{"key":"B46-20240828","first-page":"2","article-title":"Aspects of current management of thyroid orbitopathy in Asians","volume":"10","author":"J.","year":"1998","journal-title":"Asia Pac J Ophthalmol"},{"key":"B47-20240828","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.beem.2011.10.004","article-title":"Ethnic differences in the clinical presentation of Graves'ophthalmopathy","volume":"26","author":"Chung","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B48-20240828","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3341\/kjo.2013.27.6.397","article-title":"Prevalence and risk factors for thyroid eye disease among Korean dysthyroid patients","volume":"27","author":"Woo","year":"2013","journal-title":"Korean J Ophthalmol"},{"key":"B49-20240828","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4103\/ijo.IJO_2274_20","article-title":"Commentary:Thyroid eye disease-does the profile differ in India?","volume":"68","author":"Grover","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B50-20240828","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF03345276","article-title":"Relationship between cigarette smoking and Graves'ophthalmopathy","volume":"27","author":"Hegedi\u00fcs","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"B51-20240828","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1530\/eje.0.1460153","article-title":"Smoking and thyroid disorders\u2014Ameta-analysis","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"B52-20240828","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","article-title":"Risk factors for development or deterioration of Graves'ophthalmopathy","volume":"20","author":"Stan","year":"2010","journal-title":"Thyroid"},{"key":"B53-20240828","first-page":"403","article-title":"Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts-a possible explanation of the link between smoking and Graves'ophthalmopathy","volume":"7","author":"Chng","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"B54-20240828","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/eye.2016.184","article-title":"Effect of smoking on retrobulbar blood flow in thyroid eye disease","volume":"30","author":"Sadeghi-Tari","year":"2016","journal-title":"Eye"},{"key":"B55-20240828","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/biof.5520190302","article-title":"Thiocyanate overload and thyroid disease","volume":"19","author":"Erdogan","year":"2003","journal-title":"Biofactors"},{"key":"B56-20240828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","article-title":"Smoking and endocrine ophthalmopathy:Impact of smoking severity and current vs lifetime cigarette consumption","volume":"45","author":"Pfeilschifter","year":"1996","journal-title":"Clin Endocrinol"},{"key":"B57-20240828","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.2105\/AJPH.92.6.1002","article-title":"Estimates of global and regional smoking prevalence in 1995, by age and sex","volume":"92","author":"Jha","year":"2002","journal-title":"Am J Public Health"},{"key":"B58-20240828","first-page":"12","article-title":"Thyroid eye disease in New Zealand:Interaction between ethnicity and smoking status","volume":"133","author":"Angelo","year":"2020","journal-title":"N Z Med J"},{"key":"B59-20240828","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/bjo.88.1.72","article-title":"The relation of Graves'ophthalmopathy to circulating thyroid hormone status","volume":"88","author":"Kim","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"B60-20240828","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","article-title":"Effect of abnormal thyroid function on the severity of Graves'ophthalmopathy","volume":"150","author":"Prummel","year":"1990","journal-title":"Arch Intern Med"},{"key":"B61-20240828","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1089\/thy.2019.0150","article-title":"Prevention of orbitopathy by oral or intravenous steroid prophylaxis in short duration Graves'disease patients undergoing radioiodine ablation:A prospective randomized control trial study","volume":"29","author":"Vannucchi","year":"2019","journal-title":"Thyroid"},{"key":"B62-20240828","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2010.1640","article-title":"The tale of radioiodine and Graves'orbitopathy","volume":"20","author":"Ponto","year":"2010","journal-title":"Thyroid"},{"key":"B63-20240828","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves'orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"B64-20240828","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/cen.12392","article-title":"Serum selenium status in Graves'disease with and without orbitopathy:A case-control study","volume":"80","author":"Khong","year":"2014","journal-title":"Clin Endocrinol"},{"key":"B65-20240828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/01658107.2019.1566382","article-title":"Vitamin D and selenium in a thyroid eye disease population in Texas","volume":"43","author":"Sadaka","year":"2019","journal-title":"Neuroophthalmology"},{"key":"B66-20240828","doi-asserted-by":"crossref","first-page":"135347","DOI":"10.1016\/j.scitotenv.2019.135347","article-title":"Exposure to a high selenium environment in Punjab, India:Effects on blood chemistry","volume":"716","author":"Loomba","year":"2020","journal-title":"Sci Total Environ"},{"key":"B67-20240828","first-page":"209","article-title":"How to use the world's scarce selenium resources efficiently to increase the selenium concentration in food","volume":"19","author":"Haug","year":"2007","journal-title":"Microb Ecol Health Dis"},{"key":"B68-20240828","first-page":"99","article-title":"A 2018 European thyroid association survey on the use of selenium supplementation in Graves'hyperthyroidism and Graves'orbitopathy","volume":"9","author":"Negro","year":"2019","journal-title":"Eur Thyroid J"},{"key":"B69-20240828","first-page":"739","article-title":"Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves'disease","volume":"42","author":"Yasuda","year":"2012","journal-title":"Endocrin"},{"key":"B70-20240828","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/IOP.0000000000001437","article-title":"Serum vitamin D deficiency is an independent risk factor for thyroid eye disease","volume":"36","author":"Heisel","year":"2020","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B71-20240828","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2310\/JIM.0b013e31821b8755","article-title":"Vitamin D and the immune system","volume":"59","author":"Aranow","year":"2011","journal-title":"J Investig Med"},{"key":"B72-20240828","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4103\/jfmpc.jfmpc_78_18","article-title":"Vitamin D deficiency in India","volume":"7","author":"Aparna","year":"2018","journal-title":"J Family Med Prim Care"},{"key":"B73-20240828","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.4103\/ijo.IJO_1443_19","article-title":"Severity of thyroid eye disease and type-2 diabetes mellitus:Is there a correlation?","volume":"68","author":"Ramamurthy","year":"2020","journal-title":"Indian J Ophthalmol"},{"key":"B74-20240828","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/IOP.0000000000001871","article-title":"Sight-threatening thyroid eye disease:Role of diabetes mellitus and interaction with other risk factors","volume":"37","author":"Rath","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B75-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bjo.83.4.463","article-title":"Diabetes mellitus:A risk factor in patients with Graves'orbitopathy","volume":"83","author":"Kalman","year":"1999","journal-title":"Br J Opthalmol"},{"key":"B76-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eprac.2021.11.080","article-title":"Characteristics of diabetic and nondiabetic patients with thyroid eye disease in the United States:A claims-based analysis","volume":"28","author":"Patel","year":"2022","journal-title":"Endocr Pract"},{"key":"B77-20240828","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/IOP.0000000000001809","article-title":"Prospective correlation of risk of obstructive sleep apnea with severe clinical features of thyroid eye disease","volume":"37","author":"Godfrey","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B78-20240828","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/IOP.0000000000001211","article-title":"Association of risk of obstructive sleep apnea with thyroid eye disease:Compressive Optic neuropathy","volume":"35","author":"Habib","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B79-20240828","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2014-3544","article-title":"Clinical challenges of thyroid eye disease in HIV-positive patients on highly active antiretroviral therapy","volume":"100","author":"Edmunds","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B80-20240828","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41433-018-0282-1","article-title":"Immune reconstitution after alemtuzumab therapy for multiple sclerosis triggering Graves'orbitopathy:A case series","volume":"33","author":"Roos","year":"2019","journal-title":"Eye"},{"key":"B81-20240828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40618-016-0594-6","article-title":"The thyroid, the eyes and the gut:A possible connection","volume":"40","author":"Covelli","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"B82-20240828","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"Curr\u00f2","year":"2014","journal-title":"Thyroid"},{"key":"B83-20240828","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves'ophthalmopathy:Results of a prospective, single-blind, randomized study","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B84-20240828","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0002-9394(02)01970-0","article-title":"Effect of steroid pulse therapy with and without orbital radiotherapy on Graves'ophthalmopathy","volume":"135","author":"Ohtsuka","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"B85-20240828","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00417-012-2153-y","article-title":"Treatment of upper eyelid retraction related to thyroid-associated ophthalmopathy using subconjunctival triamcinolone injections","volume":"251","author":"Lee","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B86-20240828","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves'orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B87-20240828","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves'orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B88-20240828","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves'ophthalmopathy","volume":"14","author":"Marino","year":"2004","journal-title":"Thyroid"},{"key":"B89-20240828","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves'orbitopathy (MINGO):A randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B90-20240828","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0950-351X(97)80738-0","article-title":"Treating severe Graves'ophthalmopathy","volume":"11","author":"Bartalena","year":"1997","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"B91-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/WNO.0b013e318255d7c7","article-title":"Orbital radiation therapy for thyroid eye disease","volume":"32","author":"Kazim","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"B92-20240828","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ophtha.2007.10.028","article-title":"Orbital radiation for graves ophthalmopathy:A report by the American Academy of Ophthalmology","volume":"115","author":"Bradley","year":"2008","journal-title":"Ophthalmology"},{"key":"B93-20240828","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.ajo.2014.02.044","article-title":"Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease","volume":"157","author":"Shams","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"B94-20240828","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves'orbitopathy:Randomised placebo-controlled study","volume":"355","author":"Mourits","year":"2000","journal-title":"Lancet"},{"key":"B95-20240828","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0161-6420(91)32114-6","article-title":"Treatment of acute Graves orbitopathy","volume":"98","author":"Kazim","year":"1991","journal-title":"Ophthalmology"},{"key":"B96-20240828","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/IOP.0000000000001003","article-title":"Orbital radiotherapy combined with corticosteroid treatment for thyroid eye disease-compressive optic neuropathy","volume":"34","author":"Gold","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B97-20240828","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40618-015-0241-7","article-title":"Long-term outcome of Graves'orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy","volume":"38","author":"Sisti","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B98-20240828","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s11547-020-01244-5","article-title":"Is concomitant treatment with steroids and radiotherapy more favorable than sequential treatment in moderate-to-severe graves orbitopathy?","volume":"126","author":"Limone","year":"2021","journal-title":"Radiol Med"},{"key":"B99-20240828","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.ophtha.2020.01.031","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves'ophthalmopathy","volume":"127","author":"Gorman","year":"2020","journal-title":"Ophthalmology"},{"key":"B100-20240828","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0360-3016(01)01699-6","article-title":"Long-term results of irradiation for patients with progressive Graves'ophthalmopathy","volume":"51","author":"Marquez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B101-20240828","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ajoc.2017.07.001","article-title":"Tocilizumab as a steroid sparing agent for the treatment of Graves'orbitopathy","volume":"7","author":"Russell","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B102-20240828","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/IOP.0000000000001346","article-title":"Subcutaneous tocilizumab for thyroid eye disease:Simplified dosing and delivery","volume":"35","author":"Copperman","year":"2019","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B103-20240828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","article-title":"Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant graves orbitopathy:A randomized clinical trial","volume":"195","author":"Perez-Moreiras","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"B104-20240828","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves'orbitopathy:A randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B105-20240828","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves'orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B106-20240828","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/thy.2020.0269","article-title":"Efficacy profile and safety of very low-dose rituximab in patients with Graves'orbitopathy","volume":"31","author":"Vannucchi","year":"2021","journal-title":"Thyroid"},{"key":"B107-20240828","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves'ophthalmopathy:A pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye"},{"key":"B108-20240828","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B109-20240828","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/01676830590912562","article-title":"Infliximab:A novel treatment for sight-threatening thyroid associated ophthalmopathy","volume":"24","author":"Durrani","year":"2005","journal-title":"Orbit"},{"issue":"4S Suppl 1","key":"B110-20240828","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/IOP.0000000000001131","article-title":"Efficacy and safety of immunosuppressive agents for thyroid eye disease","volume":"34","author":"Strianese","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B111-20240828","first-page":"457","article-title":"Monoclonal anti-TNFalpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy","volume":"109","author":"Komorowski","year":"2007","journal-title":"Klin Oczna"},{"key":"B112-20240828","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease:A pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B113-20240828","first-page":"e216284","article-title":"Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease:A meta-analysis and matching-adjusted indirect comparison","author":"Douglas","year":"2022","journal-title":"JAMA Ophthalmol"},{"key":"B114-20240828","doi-asserted-by":"crossref","first-page":"100744","DOI":"10.1016\/j.ajoc.2020.100744","article-title":"Early experience with teprotumumab for chronic thyroid eye disease","volume":"19","author":"Ozzello","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B115-20240828","first-page":"1","article-title":"Teprotumumab for chronic thyroid eye disease","author":"Ozzello","year":"2021","journal-title":"Orbit"},{"key":"B116-20240828","article-title":"Teprotumumab for the treatment of chronic thyroid eye","author":"Ugradar","year":"2021","journal-title":"Eye"},{"key":"B117-20240828","article-title":"The role of teprotumumab in chronic, clinically active thyroid eye disease","author":"Yu","year":"2021","journal-title":"Eye"},{"key":"B118-20240828","doi-asserted-by":"crossref","first-page":"NP46","DOI":"10.1177\/1120672121991042","article-title":"Bilateral dysthyroid compressive optic neuropathy responsive to teprotumumab","volume":"32","author":"Hwang","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"B119-20240828","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1097\/IOP.0000000000001831","article-title":"Teprotumumab for dysthyroid optic neuropathy:early response to therapy","volume":"37","author":"Sears","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B120-20240828","doi-asserted-by":"crossref","first-page":"101111","DOI":"10.1016\/j.ajoc.2021.101111","article-title":"Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy:A multicenter study","volume":"23","author":"Sears","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B121-20240828","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2020.5296","article-title":"Teprotumumab for optic neuropathy in thyroid eye disease","volume":"139","author":"Slentz","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B122-20240828","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/WNO.0000000000001298","article-title":"Visual recovery of dysthyroid optic neuropathy with teprotumumab","volume":"42","author":"Lopez","year":"2022","journal-title":"J Neuroophthalmol"},{"key":"B123-20240828","doi-asserted-by":"crossref","first-page":"101075","DOI":"10.1016\/j.ajoc.2021.101075","article-title":"Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease:A report of two cases","volume":"22","author":"Chiou","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B124-20240828","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","article-title":"Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment:OPTIC-X study","volume":"129","author":"Douglas","year":"2022","journal-title":"Ophthalmology"},{"key":"B125-20240828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice:Recommendations and considerations from the OPTIC trial investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"B126-20240828","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/01945998211004240","article-title":"Thyroid eye disease, teprotumumab, and hearing loss:An evolving role for otolaryngologists","volume":"165","author":"Chern","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B127-20240828","doi-asserted-by":"crossref","first-page":"101202","DOI":"10.1016\/j.ajoc.2021.101202","article-title":"Audiology findings in patients with teprotumumab associated otologic symptoms","volume":"24","author":"Yu","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B128-20240828","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/IOP.0000000000001995","article-title":"Teprotumumab and hearing loss:Case series and proposal for audiologic monitoring","volume":"38","author":"Belinsky","year":"2022","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B129-20240828","article-title":"Ototoxicity and teprotumumab","author":"Highland","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B130-20240828","doi-asserted-by":"crossref","first-page":"e242153","DOI":"10.1136\/bcr-2021-242153","article-title":"Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease","volume":"14","author":"Hoang","year":"2021","journal-title":"BMJ. Case. Rep"},{"key":"B131-20240828","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1136\/bjo.2008.149302","article-title":"Outcome of orbital decompression for disfiguring proptosis in patients with Graves'orbitopathy using various surgical procedures","volume":"93","author":"Mourits","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"B132-20240828","doi-asserted-by":"crossref","first-page":"739236","DOI":"10.5402\/2012\/739236","article-title":"Orbital decompression in thyroid eye disease","volume":"2012","author":"Fichter","year":"2012","journal-title":"ISRN Ophthalmol"},{"key":"B133-20240828","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/IOP.0000000000000659","article-title":"The revised direct transconjunctival approach to the orbital floor","volume":"33","author":"Bernardini","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B134-20240828","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/00005537-200210000-00008","article-title":"Reduction of diplopia following endoscopic orbital decompression:The orbital sling technique","volume":"112","author":"Metson","year":"2002","journal-title":"Laryngoscope"},{"key":"B135-20240828","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0161-6420(93)31589-7","article-title":"Orbital fat removal. Decompression for Graves orbitopathy","volume":"100","author":"Trokel","year":"1993","journal-title":"Ophthalmology"},{"key":"B136-20240828","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/asj\/sjy014","article-title":"Simultaneous aesthetic eyelid surgery and orbital decompression for rehabilitation of thyroid eye disease:The one-stage approach","volume":"38","author":"Bernardini","year":"2018","journal-title":"Aesthet Surg J"},{"key":"B138-20240828","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41433-019-0664-z","article-title":"A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom","volume":"34","author":"Lee","year":"2020","journal-title":"Eye (Lond)"},{"key":"B139-20240828","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/cen.13438","article-title":"Raising awareness of Graves'orbitopathy with early warning cards","volume":"87","author":"Mitchell","year":"2017","journal-title":"Clin Endocrinol"},{"key":"B140-20240828","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1136\/bjophthalmol-2011-300487","article-title":"Validity and reliability of the TED-QOL:A new three-item questionnaire to assess quality of life in thyroid eye disease","volume":"95","author":"Fayers","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"Suppl 1","key":"B142-20240828","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000511538","article-title":"Targeting TSH and IGF-1 receptors to treat thyroid eye disease","volume":"9","author":"Neumann","year":"2020","journal-title":"Eur Thyroid J"},{"key":"B143-20240828","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/thy.2018.0349","article-title":"A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves'orbitopathy","volume":"29","author":"Marcinkowski","year":"2019","journal-title":"Thyroid"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3217_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:04:11Z","timestamp":1787756651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_3217_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":141,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_3217_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"2021-12-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}